3-甲氧基-2,2-二甲基-丙醛 | 26254-86-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-甲氧基-2,2-二甲基-丙醛
• 中文别名: 2,2-二甲氧基-3-甲氧基丙醛
• 英文名称: 3-methoxy-2,2-dimethyl-propionaldehyde
• 英文别名: methoxypivalaldehyde；3-methoxy-2,2-dimethylpropanal；3-Methoxy-2,2-dimethylpropionaldehyde
• CAS: 26254-86-4
• 化学式: C₆H₁₂O₂
• mdl: MFCD21608362
• 分子量: 116.16
• InChiKey: MSUXOWPAVUXNMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-甲氧基-2,2-二甲基-丙醛 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 以69%的产率得到methoxypivalaldoxime
  参考文献：
  名称：

  Oximinophosphoric acid derivatives, and their use for controlling pests

  摘要：

  氧化亚磷酸衍生物的化学式为##STR1##其中R.sup.1、R.sup.2和R.sup.3的含义详见说明，制备它们的方法以及它们用于控制害虫的用途。

  公开号：

  US04424215A1
• 作为产物：
  描述：

  5,5-二甲基-1,3-二噁烷 生成 3-甲氧基-2,2-二甲基-丙醛
  参考文献：
  名称：

  A New Rearrangement. Catalytic Isomerization of m-Dioxanes to β-Alkoxy Aldehydes. II. Scope and Limitations

  摘要：

  DOI：

  10.1021/ja00876a018

文献信息

• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。
• A High‐Throughput Screening Method for the Directed Evolution of Hydroxynitrile Lyase towards Cyanohydrin Synthesis
  作者：Yu‐Cong Zheng、Liang‐Yi Ding、Qiao Jia、Zuming Lin、Ran Hong、Hui‐Lei Yu、Jian‐He Xu

  DOI：10.1002/cbic.202000658

  日期：2021.3.16

  Hydroxynitrile lyases (HNLs) catalyze the enantioselective cleavage/formation of cyanohydrins. However, current methods for determining hydrocyanation are not suitable for mass screening of mutants for protein engineering of these biocatalysts. We demonstrate herein a chromogenic high‐throughput screening method for cyanohydrin synthesis that is validated by either substrate profiling or the directed evolution

  使生物氢氰化可测量：羟腈裂解酶 (HNL) 催化对映选择性裂解/形成氰醇。然而，目前确定氢氰化的方法不适合对这些生物催化剂的蛋白质工程进行突变体的大规模筛选。我们在此展示了一种用于氰醇合成的显色高通量筛选方法，该方法通过底物分析或 HNL 的定向进化进行验证。
• [EN] BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS CÉTONIQUES BICYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019012063A1

  公开（公告）日：2019-01-17

  The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

  这项发明提供了具有通式（I）的新化合物：（I）其中R1，A环和B环如本文所述，包括这些化合物的药物组合物，以及使用这些化合物的方法。
• Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
  申请人：Miyazaki Susumu

  公开号：US20050054645A1

  公开（公告）日：2005-03-10

  The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及一种由下式[I]所表示的含氮融合环化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及含有该化合物的抗HIV剂。本发明的化合物具有HIV整合酶抑制活性，并可用作预防或治疗艾滋病的药剂，或作为抗HIV剂。此外，通过与其他抗HIV剂（如蛋白酶抑制剂、逆转录酶抑制剂等）的联合使用，可使其成为更有效的抗HIV剂。由于显示出整合酶特异性高抑制活性，该化合物可作为对人体安全的药物剂，仅引起较少的副作用。
• Process for the preparation of a-methylenelactones and a-substituted hydrocarbylidene lactones
  申请人：——

  公开号：US20020143195A1

  公开（公告）日：2002-10-03

  This invention pertains to a process for making &agr;-methylenelactones and &agr;-substituted hydrocarbylidene lactones. More specifically, the present invention obtains high yields of &agr;-methylene-&ggr;-butyrolactone by heating &ggr;-butyrolactone and diethyl oxalate in the presence of a base. The second step comprises treatment of the &agr;-oxalyl enolate salt with formaldehyde to afford the &agr;-methylene-&ggr;-butyrolactone.

  这项发明涉及一种制备α-亚甲基内酯和α-取代烃基亚甲基内酯的方法。更具体地说，本发明通过在碱存在下加热γ-丁内酯和草酸二乙酯，获得高产率的α-亚甲基-γ-丁内酯。第二步包括将α-草酰基烯醚盐与甲醛处理，以得到α-亚甲基-γ-丁内酯。